Skip to main content
All lobbying filings

RIVENDELL GROUP LLP

Lobbying for GENENTECH · Biotechnology company

 Filing 3rd Quarter - Report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$40,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 2
  • MATTHEW LAWRENCE BERZOK
    Previously held: LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch
  • NICK KOLOVOS
    Previously held: LA and Counsel, Rep. Anna Eshoo

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 2
Health Issues

Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues relating to privacy and securing the data of and personal information of consumers General education on policies effecting development of pharmaceuticals, FDA approval and reimbursement.

Medicare/Medicaid

Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease;

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem